Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1682
This examiner grants 0% of resolved cases
Sarah Jane Kennedy is an examiner in Tech Center 1600 and Art Unit 1682. The data for this profile is limited, with 12 resolved cases. None of these cases resulted in an allowance, leading to a 0.0 percent allowance rate. The interview lift is also 0.0 percent. This figure reflects the fact that no cases have reached allowance, regardless of whether an interview was conducted. The median days to allowance is 1321. This 1321-day figure represents the timeline for cases in the record, although none have been successful.
Because there are only 12 resolved cases and a 0.0 percent allowance rate, practitioners should be prepared for a very challenging prosecution. The 1321-day median and 0.0 percent interview lift suggest that standard strategies have not yet been successful in Art Unit 1682 under this examiner. Applicants should consider alternative approaches given this difficult baseline and the lack of successful outcomes in the current data.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18271793 | PREDICTION OF AN OUTCOME OF A COLORECTAL CANCER SUBJECT | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 17633922 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF BLADDER CANCER | Final Rejection | The Regents of the University of California |
| 18972277 | IN SITU NUCLEIC ACID ANALYSIS USING PROBE PAIR LIGATION | Final Rejection | The Johns Hopkins University |
| 17790293 | IN SITU RNA ANALYSIS USING PROBE PAIR LIGATION | Final Rejection | The Johns Hopkins University |
| 18069078 | PHASE PROTECTIVE REAGENT FLOW ORDERING | Final Rejection | Singular Genomics Systems, Inc. |
| 18696031 | METHOD FOR PREDICTING RESPONSE TO CANCER IMMUNOTHERAPY BY USING DNA METHYLATION ABERRATION IN LINE-1 | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17924832 | METHOD FOR PREDICTING PROGNOSIS OF PATIENTS HAVING EARLY BREAST CANCER | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17927491 | ANALYTE DETECTION METHOD | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 17907791 | BIOMARKER COMPOSITION FOR DIAGNOSING DIFFUSE TYPE GASTRIC CANCER, AND MEDICAL USE THEREOF | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18009945 | METHODS FOR DETECTING AND PREDICTING CANCER AND/OR CIN3 | Final Rejection | UCL Business Ltd |
| 18008953 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS | Final Rejection | Illumina, Inc. |
| 17921711 | DETECTING MELANOMA | Non-Final OA | Exact Sciences Corporation |
| 18718992 | METHOD FOR DETECTING INTEGRATION SITE | Non-Final OA | NANJING GENSCRIPT BIOTECH CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy